Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
974 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,928 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844551 | ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC | not yet recruiting | Phase 2 | 40 | Huashan HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07836049 | PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC | not yet recruiting | Phase 2 | 20 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830355 | Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes | not yet recruiting | Phase 2 | 75 | Shanghai Chest HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07827872 | Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 300 | caohaotianOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825597 | Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma | not yet recruiting | — | 25 | Washington University School of MedicineOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07822906 | Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery | not yet recruiting | — | 100 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823270 | Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 33 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823309 | Quad Shot Versus Split Course Radiotherapy in Incurable Head and Neck Cancer(QSSC-HN) | not yet recruiting | N/A | 40 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07808359 | Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma(APOLO) | not yet recruiting | Phase 2 | 58 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07513324 | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) | not yet recruiting | Phase 2 | 116 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | not yet recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07809100 | Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma(MIC-VADS) | not yet recruiting | N/A | 120 | Centre Hospitalier Sud FrancilienOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809191 | Hair Regrowth Following Partial Thickness Removal of SSCIS | not yet recruiting | N/A | 15 | The Cooper Health SystemOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07509099 | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC | not yet recruiting | Phase 3 | 316 | Ji DongmeiOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07799077 | Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07797738 | Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma(OPSCC) | not yet recruiting | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07484139 | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)(NEO COMBAT XL) | not yet recruiting | Phase 2 | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796126 | Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status(HNSCC) | not yet recruiting | Phase 2 | 22 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07791745 | A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 362 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07788950 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | not yet recruiting | Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07784855 | Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer | not yet recruiting | N/A | 180 | West Virginia UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | not yet recruiting | Phase 2 | 85 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07778056 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study(TTE-ESCC) | not yet recruiting | — | 400 | Henan Cancer HospitalOTHER_GOV | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Shanghai East HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778732 | Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07769658 | Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma(ESCC-MRI-TRG) | not yet recruiting | — | 500 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07769866 | Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC | not yet recruiting | N/A | 68 | RenJi HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07766889 | Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07767266 | Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer | not yet recruiting | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07418034 | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)(SAVED) | not yet recruiting | Phase 2 | 132 | University of Maryland, BaltimoreOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07552558 | Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Phase 1 / Phase 2 | 45 | Washington University School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.(DUNP19) | not yet recruiting | Phase 1 | 16 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07758621 | SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC | not yet recruiting | Phase 3 | 340 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 11, 2026 | clinicaltrials |
| NCT07751276 | Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC | not yet recruiting | Phase 2 | 142 | Yanjie Zhang, MDOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07751289 | Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma(neo-Recur) | not yet recruiting | Phase 2 | 217 | Yanjie Zhang, MDOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07677475 | MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 65 | Dongguan People's HospitalOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07745803 | Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma | not yet recruiting | — | 4,000 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
Data updated 22 hours agoSource updated Sep 28, 2026source: clinicaltrials